Drugs / NK520
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06541405 | Jul 2024 → Jun 2025 | acute myeloid leukemia | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT06541444 | Jul 2024 → Jun 2026 overdue | acute myeloid leukemia | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NK520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06541405 ↗ |
| Route | Intravenous | “NK520 will be administered by intravenous injection.” NCT06541405 ↗ |